C-Path and NICHD Real-World Data Collaboration for Neonatal Drug Development

The Critical Path Institute (C-Path) and the National Institute of Health and Human Development (NICHD) have joined a real-world data (RWD) sharing agreement to seek new drugs for neonatal infants. The collaboration will produce RWE from data points from the Surfactant Positive Airway Pressure and Pulse Oximetry Trial in Extremely Low Birth Weight Infants (SUPPORT) trial.

According to a press release from C-Path, “Coordinated by INC, C-Path’s Data Collaboration Center will develop the Real-World Data and Analytics Platform (RW-DAP) as an integrated database and analytics hub designed to be used in generating actionable RWE. In turn, such actionable RWE will be generated by C-Path’s Quantitative Medicine Program, focusing on mathematical models of disease progression, laboratory values, clinical outcome measures and biomarkers that can be used to design optimal trials in this population.”

Read the entire press release by clicking here.

(Source: C-Path, December 1^st, 2021)